Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Recruiting 34Active not recruiting 14Not yet recruiting 7Completed 7Suspended 4Terminated 3Enrolling by invitation 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Glioblastoma 1Eyelid Squamous Cell Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 25Magnetic Resonance Spectroscopy 17Biopsy 15Cyclophosphamide 6venetoclax 5Vincristine 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Azacitidine 4pembrolizumab 3fludarabine phosphate 3X-Rays 3Taxes 3Radiation 3Injections 3Cetuximab 3trastuzumab deruxtecan 2fludarabine 2decitabine and cedazuridine drug combination 2cemiplimab 2Tacrolimus 2Standard of Care 2Sirolimus 2Radiotherapy 2Radiosurgery 2Prednisone 2Practice Guidelines as Topic 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Suspended × Surgical Procedures, Operative × 90 days × Clear all
NCT06325683 2026-05-26

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Suspended
184 enrolled
CNS

Glioblastoma

NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

NCT06246344 2026-05-01

Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Shandong Cancer Hospital and Institute

Suspended
128 enrolled
Gastrointestinal

Rectal Neoplasms

NCT02366819 2026-03-30

Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

University of Chicago

Phase 4 Suspended
36 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡